Home > Articles > Published articles > Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation |
Date: | 2022 |
Abstract: | Nuclear magnetic resonance (NMR)-based advanced lipoprotein tests have demonstrated that LDL and HDL particle numbers (LDL-P and HDL-P) are more powerful cardiovascular (CV) risk biomarkers than conventional cholesterol markers. Of interest, in people living with HIV (PLHIV), predictors of preclinical atherosclerosis and vascular dysfunction may be associated with impaired immune function. We previously stated that immunological non-responders (INR) were at higher CV risk than immunological responders (IR) before starting antiretroviral therapy (ART). Using Liposcale tests, we characterized the lipoprotein profile from the same cohort of PLHIV at month 12 and month 36 after starting ART, intending to explore what happened with these indicators of CV risk during viral suppression. ART initiation dissipates the differences in lipoprotein-based CV risk markers between INR and IR, and only an increase in the number of HDL-P was found in INR + IR when compared to controls (p = 0. 047). Interestingly, CD4 T-cell counts negatively correlated with medium HDL-P concentrations at month 12 in all individuals (ρ = −0. 335, p = 0. 003). Longitudinal analyses showed an important increase in LDL-P and HDL-P at month 36 when compared to baseline values in both IR and INR. A proper balance between a proatherogenic and atherogenic environment may be related to the reconstitution of CD4 T-cell count in PLHIV. |
Grants: | Instituto de Salud Carlos III PI16/00503 Instituto de Salud Carlos III PI19/01337 Instituto de Salud Carlos III PI20/00326 Instituto de Salud Carlos III RD16/0025/0006 Instituto de Salud Carlos III CB21/13/00020 Instituto de Salud Carlos III INT20/00031 Instituto de Salud Carlos III CP19/00146 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017SGR948 |
Note: | Altres ajuts: European Regional Development Fund/European Social Fund, "A way to make Europe"/"Investing in your future"; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas; Universitat Rovira i Virgili (2019PMF-PIPF-18), Martí Franquès Research Fellowship Programme; IISPV (project "2019/IISPV/05", Boosting Young Talent); GeSIDA (III Premio para Jóvenes Investigadores 2019). |
Rights: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
Language: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Subject: | Antiretroviral therapy ; Cardiovascular risk ; Immunological non-responder ; Lipoproteins ; Longitudinal analysis ; Nuclear magnetic resonance ; People living with HIV |
Published in: | International journal of molecular sciences, Vol. 23 Núm. 15 (august 2022) , p. 8071, ISSN 1422-0067 |
12 p, 3.0 MB |